Monoclonal Antibodies May No Longer Be a Match for Emerging COVID Strains
Tixagevimab/cilgavimab (Evusheld) and bebtelovimab are likely ineffective against approximately 60% of currently circulating Omicron variants, creating a big gap in...
Tixagevimab/cilgavimab (Evusheld) and bebtelovimab are likely ineffective against approximately 60% of currently circulating Omicron variants, creating a big gap in...
The virus that causes COVID-19 is bringing more variants our way, requiring a few changes to the fight against it.The BA.5...
When it comes to viral transmission, Connecticut faces good news and bad news this fall.First, the good news: In recent...
JONGHO SHINBy Claire MarshallRural affairs correspondent, BBC NewsThe UK's main facility for dealing with viruses that jump from animals to...
BEIJING, Nov 20 (Reuters) - New coronavirus case numbers held steady in China near April peaks on Sunday as many...
If you’re a Long COVID patient with headaches, brain fog, or other neurological symptoms, another coronavirus could be to blame—at...
BEIJING, Nov 20 (Reuters) - New coronavirus case numbers held steady in China near April peaks on Sunday as many...
China-developed oral drug for COVID-19 treatment AzvudineChina's first domestically developed oral drug for COVID-19 treatment was removed from shelves of...
BEIJING (AP) — China on Sunday announced its first new death from COVID-19 in nearly half a year as strict...
Attachments 1. Introduction The Asia-Pacific region has been severely affected by the COVID-19 pandemic. The economic and health recovery from...